Indian pharma majorLupin (BSE: 500257) and Nichi-Iko (TYO: 4541) have entered into an agreement for the distribution, promotion and sale of Lupin’s recently-filed biosimilar etanercept (YLB113) in Japan.
The drug is a copy of Enbrel (etanercept), Amgen (Nasdaq: AMGN) and Pfizer’s (NYSE: PFE) immunology drug.
Developed by YL Biologics, a joint venture between Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo, the product will be launched by Nichi-Iko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze